Sirolimus for Vincristine‐Resistant Kasabach–Merritt Phenomenon: Report of Eight Patients

• Published in: Pediatric dermatology Vol. 34; no. 3; pp. 261 - 265
• Main Authors: Wang, Huaijie, Duan, Yitao, Gao, Ya, Guo, Xinkui
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2017
• Subjects: Blood Chemical Analysis; Children; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infant; Kasabach-Merritt Syndrome - diagnosis; Kasabach-Merritt Syndrome - drug therapy; Male; Multidrug resistance; Patient Safety; Rapamycin; Remission Induction; Retrospective Studies; Sampling Studies; Side effects; Sirolimus - administration & dosage; Skin Neoplasms - diagnosis; Skin Neoplasms - drug therapy; Toxicity; Treatment Outcome; Tumors; Vincristine; Vincristine - therapeutic use

Background The use of sirolimus for patients with multidrug‐resistant Kasabach–Merritt phenomenon (KMP) has been reported in recent years. We present the experience of a single center in treating vincristine‐resistant KMP using sirolimus alone. Methods Children with vincristine‐resistant KMP who wer...